SRZNW — Surrozen, Inc.

Surrozen (SRZNW) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Surrozen reported cash, cash equivalents, and marketable securities of approximately $76 million at the end of 2022.
• The company anticipates a cash runway extending into the second half of 2024, following a restructuring aimed at reducing operating expenses by about 15% in 2023 compared to 2022.
• A partnership with Boehringer Ingelheim was executed in Q4 2022 for the development of SZN-413, which could trigger a $10 million milestone payment upon candidate nomination by year-end 2023.

2. Strategic Updates and Business Highlights

• Surrozen is focused on leveraging its proprietary Wnt pathway technologies to develop tissue-selective antibodies for severe diseases, with two lead clinical programs: SZN-043 for severe alcoholic hepatitis and SZN-1326 for inflammatory bowel disease (IBD).
• SZN-043 has enrolled its first patient in a Phase I trial targeting liver regeneration, while SZN-1326's Phase I trial was paused due to observed liver enzyme elevations but is set to resume with a modified dosing strategy.
• The company has filed or licensed over 20 patent families related to its Wnt pathway research, reinforcing its intellectual property position.

3. Forward Guidance and Outlook

• Surrozen expects to have data from the Phase I trial of SZN-043 in chronic liver disease patients by the end of 2023, with plans to initiate a Phase Ib trial in severe alcoholic hepatitis in 2024.
• For SZN-1326, the company anticipates proof-of-concept data in ulcerative colitis patients in the second half of 2024.
• The company is also progressing on additional research programs targeting corneal diseases and severe dry eye, with potential development candidates expected in 2023.

4. Bad News, Challenges, or Points of Concern

• The company disclosed adverse events related to liver enzyme elevations observed in clinical trials, particularly for SZN-1326, leading to a voluntary pause in enrollment. This raised concerns about the safety profile of both lead candidates.
• There is uncertainty regarding the implications of liver-specific effects observed in both SZN-043 and SZN-1326, with ongoing investigations needed to understand the mechanisms behind these transaminase elevations.
• The need for careful dose management and the potential for complications in hepatically impaired patients were highlighted as significant challenges.

5. Notable Q&A Insights

• During the Q&A, management clarified that the Phase I study for SZN-043 is targeting chronic liver disease patients, which may include those with fibrosis but not necessarily cirrhosis.
• Questions about the dosing strategy for SZN-1326 revealed that the company is adopting a MABEL (minimum anticipated biological effect level) approach to mitigate risks associated with previously observed adverse events.
• Management expressed confidence in the therapeutic potential of both candidates, emphasizing that the observed liver enzyme elevations may be linked to the regenerative effects of Wnt signaling rather than direct toxicity.
• The half-life of SZN-1326 was noted to be approximately 5 days, with potential for less frequent dosing regimens based on biological effects extending beyond the antibody's half-life.

Overall, while Surrozen is making progress in its clinical programs and strategic partnerships, it faces significant challenges related to safety concerns that could impact the development timelines and regulatory pathways for its lead candidates.